BPC-157

BPC-157 is primarily studied for tissue repair and healing. Published research has investigated its effects on tendons, ligaments, muscles, the gastrointestinal tract, bone, and neurological tissue. It is not FDA-approved for any therapeutic use in humans.

Legal status varies by country. In the US, it was placed on the FDA's Category 2 restricted list in 2023 but is expected to be reinstated for compounding under 503A. In many other countries, it is available as a research chemical. See the Legal Status section above for a country-by-country breakdown.

BPC-157 is most commonly administered via subcutaneous injection, typically near the site of injury for localized effects. It can also be injected intramuscularly. The peptide must first be reconstituted from lyophilized powder using bacteriostatic water. See our Mixing & Administration Guide for step-by-step instructions.

Based on limited human data and anecdotal reports, side effects appear mild and may include nausea, dizziness, injection site redness, and headache. The 2025 pilot study found no serious adverse events at IV doses up to 20mg. However, long-term human safety data is not yet available.

Some research has been conducted using oral administration of BPC-157, particularly for gastrointestinal applications. Oral bioavailability is believed to be lower than injectable routes, and oral capsule forms are available from some compounding pharmacies. Research on oral vs. injectable efficacy is limited.

Anecdotal reports suggest effects may be noticed within a few days to two weeks, depending on the severity of the condition being addressed. Research protocols typically run 4–8 weeks. Individual response varies significantly.

Yes. Lyophilized (powder) BPC-157 should be stored at -20°C for long-term storage or 2–8°C (refrigerator) for short-term. Once reconstituted, the solution should be refrigerated at 2–8°C and used within 28 days. Avoid repeated freeze-thaw cycles.

No. BPC-157 is a peptide — a short chain of 15 amino acids. It is not a steroid, not a hormone, and does not directly affect testosterone, estrogen, or other steroid hormones. Its mechanism of action involves growth factors, nitric oxide pathways, and cell signaling — entirely different from anabolic steroids.

This is an area of theoretical concern, not established fact. Because BPC-157 promotes angiogenesis (new blood vessel formation), there is a hypothesis that it could theoretically support tumor growth in individuals with existing cancers. No published study has demonstrated a carcinogenic effect. However, most researchers recommend avoiding BPC-157 in individuals with active malignancies as a precaution.

Both are tissue repair peptides, but they work through different mechanisms. BPC-157 primarily promotes angiogenesis, modulates the nitric oxide system, and enhances growth factor receptor expression. TB-500 (Thymosin Beta-4) acts mainly through actin regulation, cell migration, and anti-inflammatory pathways. They are frequently stacked together for synergistic effects.